About Crinetics
Crinetics is a publicly listed company based in San Diego (United States) founded in 2008 by Scott Struthers, and was acquired by Vertex Pharmaceuticals in July 2026. Crinetics has raised $103.5 million across 19 funding rounds from investors including Vertex Pharmaceuticals, NIH and HHS. The company has 437 employees. Its chief executive, as recorded, is Scott Struthers. Its website crinetics.com draws about 22 thousand monthly visits. Crinetics offers products and services including Paltusotine, Atumelnant, and CRN09682. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is Crinetics Pharmaceuticals, Inc. Its competitors include Neurocrine, MBX Biosciences and Radionetics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapies for the treatment of endocrine-related diseases and cancers. The company focuses on the development of drugs for endocrine disorders and cancers in the areas of neuroendocrinology, reproductive medicine, and womens health. Its lead candidate is CRN04777, an oral SST5 agonist for hypoglycemia.
- Headquarters San Diego, United States
- Employees 437
- Founders Scott Struthers
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website crinetics.com
- Social LinkedIn X Facebook YouTube
- Acquired by Vertex Pharmaceuticals (Jul 2026)
- Legal Name Crinetics Pharmaceuticals, Inc.
- Annual Revenue$1.04 M (USD)-74.11as on Dec 31, 2024
- Net Profit-$298.41 M (USD)-39.1as on Dec 31, 2024
- EBITDA-$336.07 M (USD)-51.72as on Dec 31, 2024
- Total Equity Funding$103.5M (USD)
in 19 rounds
- Latest Funding Round$350M (USD), Post-IPO
Mar 2024
- InvestorsVertex Pharmaceuticals
& 13 more
- Employee Count437
- Acquired byVertex Pharmaceuticals
(Jul 2026)
Products & Services of Crinetics
Crinetics offers a comprehensive portfolio of products and services, including Paltusotine, Atumelnant, and CRN09682.
Therapy for acromegaly and carcinoid syndrome treatment
Treatment for congenital adrenal hyperplasia
Targets neuroendocrine tumors and SST2-expressing cancers
Apps and channels of Crinetics
its YouTube channel Crinetics Pharmaceuticals has 97 subscribers and 25 videos.
Videos from Crinetics
The most watched videos on Crinetics's YouTube channel, Crinetics Pharmaceuticals (97 subscribers). Click a video to play it here.
More on Crinetics Pharmaceuticals.
Funding Insights of Crinetics
Crinetics has successfully raised a total of $103.5M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $350 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $103.5M
- Total Rounds 19
- Last Round Post-IPO — $350M
- Investors Count 13
Latest 10 of 19 funding rounds of Crinetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $350M | Post-IPO | – | – | – |
| Jul 2021 | $15M | Post-IPO | – | – | |
| Feb 2018 | $63.5M | Series B | – | Perceptive Advisors | |
| Sep 2017 | $299,510 | Grant | – | – | |
| Aug 2017 | $2.19M | Grant | – | – | |
| Nov 2015 | $40M | Series A | – | 5AM Ventures, Versant Ventures | – |
| Apr 2015 | $2.7M | Grant | – | – | |
| Apr 2015 | $326,121 | Grant | – | – | |
| Jan 2015 | $1.5M | Grant | – | – | |
| Apr 2014 | Grant | – | – |
14 investors in total: 14 institutional.
Investors in Crinetics
Crinetics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Research on neurological disorders and stroke is conducted and funded. | ninds.nih.gov | Bethesda, United States | ||
Child health and human development services are provided nationwide. | 1962 | nichd.nih.gov | Bethesda, United States |
Investor details for Crinetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Crinetics
172 people are tracked at Crinetics (100 in leadership, 13 in board & advisors, 59 in team); the tracked headcount is 437.
| Name | Role | Group |
|---|---|---|
Scott Struthers | Founder & CEO | Leadership |
Imaobong Vanderpool | Director Of Field Medical Excellence | Leadership |
Cosina Mui | Director, Clinical Operations | Leadership |
Adriana Cabré | Chief Human Resources Officer | Leadership |
Niccole Le | Chief Of Staff To The COO & Head Of Alliance Management | Leadership |
Ron Sullivan | Associate Director Quality Assurance | Leadership |
Aby Augustine M.D. | Senior Medical Director - Pharmacovigilance ( Ta- Endocrine Disorders & Oncology) | Leadership |
Daria Davis Yatak Pharmd | Regional Medical Affairs Director, South Central | Leadership |
Marc Wilson | Chief Financial Officer | Leadership |
CJ Woodworth | Executive Administrator to the CEO & Executive Lead | Leadership |
Kika Teudt | Senior Director, Regulatory Affairs | Leadership |
Darren Allender | Director Project Management, Commercialization | Leadership |
Vandana Chawla | Senior Director, R&D Counsel | Leadership |
Knikki Childs Pendleton | Executive Director, Field Medical | Leadership |
Quyen Doan | Sr. Director, Talent Acquisition & New Employee Experience | Leadership |
Taylor Hindle | Associate Director, Human Resources Business Partner | Leadership |
Rhianna Laker | Director | Leadership |
Jacob McCracken | VP Financial Planning & Analysis | Leadership |
Eyad Elseidny | Associate Director, Human Resources Business Partner | Leadership |
Natalie Rossingnol | VP, Project & Portfolio Management | Leadership |
152 more people are available in the full profile.
Complete people profiles for Crinetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Crinetics
Crinetics is a publicly listed company on the NASDAQ with ticker symbol CRNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jul 2018
- Listed onNASDAQ: CRNX
- Listed entityCrinetics Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS22663K1079
- Share price$37.48 (-13.82% on the day) · 2026-05-11
- Market capitalisation$3.95B
- EPS (diluted, trailing year)$-5.13
- Volume (last session)4,707,630
- Analyst consensusStrong buy
Financials of Crinetics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $1.0M | -$298.4M | -$336.1M |
| 2023 | $4.0M | -$214.5M | -$221.5M |
| 2022 | $4.7M | -$163.9M | -$166.5M |
| 2021 | $1.1M | -$107.6M | -$106.4M |
| 2020 | -$73.8M | -$73.8M |
Detailed financial statements for Crinetics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Crinetics
5 dated milestones of Crinetics across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Crinetics is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $350.0M.
- Exit Acquired by Vertex Pharmaceuticals.
Competitors of Crinetics
Crinetics has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, MBX Biosciences and Radionetics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| mbxbio.com | 2018 | Carmel, United States | $215.6M | 11 | Drugs for rare endocrine diseases are developed and advanced. | |
| radionetics.com | 2021 | San Diego, United States | $136.71M | Peptide-targeted radiopharmaceuticals for cancer treatment are developed. |
Detailed competitors of Crinetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Crinetics
The website of Crinetics (crinetics.com) receives about 21.7K visits a month and ranks #1,355,406 among all websites worldwide, #1,757 in Biotechnology and Pharmaceuticals.
- Monthly visits21.7K
▼ 8.9% vs previous month
- Unique visitors8.4K
per month
- Global rank#1,355,406
among all websites
- Category rank#1,757
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.6
- Average visit15 sec
- DevicesDesktop 25% · Mobile 75%
Websites whose visitors overlap most with Crinetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ambrx.com | 100% | 1.7K | #3,844,291 | View details | |
| ajibio-pharma.com | 98% | 4.7K | #3,787,378 | View details | |
| btsresearch.com | 94% | View details | |||
| bioagilytix.com | 93% | 41.6K | #919,146 | View details | |
| aspenneuroscience.com | 93% | 6.1K | #2,537,044 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Crinetics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Crinetics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Crinetics
Complete news archive for Crinetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crinetics
Crinetics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Crinetics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Scott Struthers is the CEO of Crinetics, as recorded in our data. They have also founded this company.
Crinetics is a funded company, having raised a total of $103.5M across 19 funding rounds to date.
Crinetics has 437 employees.
Annual revenue of Crinetics is $1.04M as on Dec 31, 2024.
Developer of therapies for the treatment of endocrine-related diseases and cancers. The company focuses on the development of drugs for endocrine disorders and cancers in the areas of neuroendocrinology, reproductive medicine, and womens health. Its lead candidate is CRN04777, an oral SST5 agonist for hypoglycemia.
Crinetics's top competitors include Neurocrine, MBX Biosciences and Radionetics.
Crinetics offers Paltusotine, Atumelnant, and CRN09682.
Yes, Crinetics is publicly traded on NASDAQ under the ticker symbol CRNX.
Crinetics has 14 investors. Key investors include Vertex Pharmaceuticals, NIH, HHS, Orbimed, and RA Capital.
Crinetics operates through Crinetics Pharmaceuticals, Inc..